# Cellular Immunotherapy for Septic Shock

> **NCT03369275** · PHASE2 · UNKNOWN · sponsor: **Ottawa Hospital Research Institute** · enrollment: 114 (estimated)

## Conditions studied

- Septic Shock
- Sepsis
- Pathologic Processes
- Shock
- Infection
- Systemic Inflammatory Response Syndrome
- Inflammation

## Interventions

- **BIOLOGICAL:** Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03369275
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-03
- **Primary completion:** 2020-02
- **Final completion:** 2020-10
- **Target enrollment:** 114 (ESTIMATED)
- **Last updated:** 2017-12-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03369275

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03369275, "Cellular Immunotherapy for Septic Shock". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03369275. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*